30S Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Saniona AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.21 |
| 52 Week High | SEK 0.66 |
| 52 Week Low | SEK 0.12 |
| Beta | 0.97 |
| 11 Month Change | -39.52% |
| 3 Month Change | -39.17% |
| 1 Year Change | -67.73% |
| 33 Year Change | -78.84% |
| 5 Year Change | -92.09% |
| Change since IPO | -92.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 30S | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -0.7% | -0.02% |
| 1Y | -67.7% | -17.2% | 8.2% |
Return vs Industry: 30S underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 30S underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 30S volatility | |
|---|---|
| 30S Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 30S's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 30S's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 22 | Thomas Feldthus | www.saniona.com |
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome.
Saniona AB (publ) Fundamentals Summary
| 30S fundamental statistics | |
|---|---|
| Market cap | €28.26m |
| Earnings (TTM) | -€7.11m |
| Revenue (TTM) | €2.16m |
13.1x
P/S Ratio-4.0x
P/E RatioIs 30S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 30S income statement (TTM) | |
|---|---|
| Revenue | SEK 24.88m |
| Cost of Revenue | SEK 5.50m |
| Gross Profit | SEK 19.38m |
| Other Expenses | SEK 101.19m |
| Earnings | -SEK 81.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 77.91% |
| Net Profit Margin | -328.83% |
| Debt/Equity Ratio | 574.8% |
How did 30S perform over the long term?
See historical performance and comparison